BioCentury
ARTICLE | Clinical News

Ozurdex dexamethasone intravitreal implant regulatory update

February 23, 2015 8:00 AM UTC

The U.K.’s NICE issued a preliminary appraisal recommending Ozurdex dexamethasone from Allergan to treat diabetic macular edema (DME). The recommendation is restricted to patients with an intraocular lens who did not respond to non-corticosteroids. Ozurdex is approved in adult patients with visual impairment due to DME who are pseudophakic or who are considered insufficiently responsive to or unsuitable for non-corticosteroid therapy. Comments are due March 12, with a second appraisal committee meeting scheduled for March 24. ...